Want to see IN:APLLTD full AI Analyst Report?
Top Page
Alembic Pharmaceuticals Limited
(APLLTD)
Select Model
Select Model
Rating:70Outperform
Price Target:
₹909.00
▲(11.67% Upside)
Action:Upgraded
Date:08/19/26
The score is anchored by solid financial performance (steady growth, strong balance sheet) but held back by uneven cash-flow consistency. Technicals are supportive with price above key moving averages and positive MACD. Valuation is the main drag due to a mid-20s P/E and only a modest dividend yield.
Positive Factors
Steady Revenue Growth
Sustained revenue expansion indicates ongoing demand across Alembic's pharmaceutical portfolio. Continued growth in formulations and APIs can support scale, market reach, and operating resilience over the next several quarters.
Negative Factors
Volatile Cash Generation
The sharp year-to-year swing in operating and free cash flow signals working-capital and execution risk. Even with the 2026 rebound, inconsistent conversion of earnings into cash can constrain investment flexibility and financial predictability.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Sustained revenue expansion indicates ongoing demand across Alembic's pharmaceutical portfolio. Continued growth in formulations and APIs can support scale, market reach, and operating resilience over the next several quarters.
Read all positive factors
Alembic Pharmaceuticals Limited (APLLTD) vs. iShares MSCI India ETF (INDA)
Market Cap
₹157.17B
Dividend Yield1.48%
Average Volume (3M)24.96K
Price to Earnings (P/E)22.9
Beta (1Y)1.02
Revenue Growth14.12%
EPS Growth14.98%
CountryIN
Employees17,244
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)35.27
Shares Outstanding196,563,130
10 Day Avg. Volume11,758
30 Day Avg. Volume24,963
Financial Highlights & Ratios
PEG Ratio1.23
Price to Book (P/B)2.30
Price to Sales (P/S)1.77
P/FCF Ratio50.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)37.69
Revenue Forecast (FY)₹84.17B
Alembic Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Alembic Pharmaceuticals Limited is a pharmaceutical firm that develops, manufactures, and markets medicinal products both domestically in India and across international markets. Its offerings encompass active pharmaceutical ingredients (APIs) and ...
How the Company Makes Money
Alembic Pharmaceuticals makes money primarily by selling pharmaceutical products across domestic and international markets, with revenue generated from multiple streams: (1) Formulations (finished dosage medicines): The company earns revenue by ma...
Alembic Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.84B | 73.45B | 66.72B | 62.29B | 56.53B | 53.06B |
| Gross Profit | 34.61B | 33.10B | 47.91B | 44.33B | 38.78B | 38.08B |
| EBITDA | 11.66B | 11.06B | 9.89B | 9.14B | 6.96B | 8.59B |
| Net Income | 6.93B | 6.75B | 5.83B | 6.16B | 3.42B | 5.21B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 87.63B | 77.73B | 64.46B | 61.83B | 71.22B |
| Cash, Cash Equivalents and Short-Term Investments | 1.96B | 2.03B | 901.00M | 1.20B | 754.80M | 610.90M |
| Total Debt | 0.00 | 14.30B | 12.57B | 5.13B | 7.22B | 7.17B |
| Total Liabilities | -56.69B | 30.94B | 25.83B | 16.27B | 18.12B | 18.84B |
| Stockholders Equity | 56.69B | 56.75B | 51.91B | 48.18B | 43.70B | 52.38B |
Cash Flow | ||||||
| Free Cash Flow | 1.69B | 2.61B | -4.76B | 4.76B | 2.81B | 1.27B |
| Operating Cash Flow | 4.03B | 6.95B | 879.70M | 8.03B | 7.24B | 5.52B |
| Investing Cash Flow | -2.87B | -5.07B | -5.68B | -3.21B | -4.48B | -3.72B |
| Financing Cash Flow | -649.70M | -756.50M | 4.44B | -4.38B | -2.62B | -2.17B |
Alembic Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹170.25B | 27.93 | ― | 0.36% | 7.93% | 21.51% | |
74 Outperform | ₹150.19B | 12.92 | ― | 0.54% | -20.73% | -32.59% | |
70 Outperform | ₹157.17B | 22.92 | ― | 1.48% | 14.12% | 14.98% | |
67 Neutral | ₹292.43B | -95.62 | ― | 0.06% | 0.78% | -420.81% | |
64 Neutral | ₹214.75B | 33.09 | ― | 0.20% | 24.83% | 36.88% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹151.76B | 44.86 | ― | 0.50% | 16.27% | -23.50% |
* General Sector Average
IN:APLLTD
Alembic Pharmaceuticals Limited
817.80
-119.94
-12.79%
IN:ALIVUS
Glenmark Life Sciences Limited
1,399.50
452.83
47.83%
IN:GRANULES
Granules India Limited
883.20
358.89
68.45%
IN:JUBLPHARMA
Jubilant Pharmova Limited
1,019.00
-113.93
-10.06%
IN:NATCOPHARM
NATCO Pharma Limited
826.25
-14.57
-1.73%
IN:PPLPHARMA
Piramal Pharma Limited
218.10
18.90
9.49%
Alembic Pharmaceuticals Limited Corporate Events
Alembic Pharmaceuticals Sets August 5 Virtual AGM, Announces E-Voting and Dividend Record Date
Jul 11, 2026
Alembic Pharmaceuticals has notified exchanges and shareholders that its 16th Annual General Meeting will be held on August 5, 2026, via video conferencing and other audio-visual means, in line with provisions of the Companies Act and SEBI listing...
Alembic Pharma Schedules One-on-One Meets With Key Institutional Investors
Jun 19, 2026
Alembic Pharmaceuticals has disclosed that its management will hold a series of one-on-one meetings with key institutional investors, including HDFC Mutual Fund, Tata Mutual Fund, DSP Mutual Fund, and HDFC Life Insurance Company, between June 22 a...
Alembic Pharmaceuticals Plans One-on-One Meets With Key Institutional Investors
Jun 19, 2026
Alembic Pharmaceuticals has scheduled a series of one-on-one investor meetings with major institutional investors, including HDFC Mutual Fund, Tata Mutual Fund, DSP Mutual Fund, and HDFC Life Insurance Company. The meetings, to be held in Mumbai a...
Alembic Pharmaceuticals Lines Up One-on-One Meetings With Key Institutional Investors
Jun 19, 2026
Alembic Pharmaceuticals has scheduled one-on-one investor meetings with major institutional investors, including HDFC Mutual Fund, Tata Mutual Fund, DSP Mutual Fund, and HDFC Life Insurance Company. The meetings, to be held in Mumbai and via video...
Alembic Pharma Sets Virtual AGM, Record Date and Updates Dividend, KYC, and TDS Rules
Jun 9, 2026
Alembic Pharmaceuticals has announced that its 16th Annual General Meeting will be held on 5 August 2026 at 4:00 p.m. IST via video conferencing or other audio-visual means, in line with provisions of the Companies Act and SEBI listing regulations...
Alembic Pharma Takes 45% Stake in New Canadian Drug Venture
Jun 6, 2026
Alembic Pharmaceuticals Limited has signed a shareholders’ agreement to invest in a newly incorporated Canadian company, 17989377 Canada Inc., alongside Difgen Holdings LLC and another minority investor. Alembic and Difgen will each hold a 4...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.